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The aim of this study was to evaluate the influence of cyclosporine A (CsA) on glomerular growth 
and the effect of mizoribine (MZR) and losartan (LSAR) on CsA-induced nephropathy in young rats. 
Six-week-old male Sprague-Dawley rats maintained on a low salt diet were given CsA (15 mg/kg), 
CsA and LSRT (30 mg/kg/day), CsA and MZR (5 mg/kg), or a combination of CsA, LSRT, and MZR for 4 
and 7 weeks (two experiments) and compared with control group (olive oil-treated). Histopathology 
and glomerular size, inflammatory and fibrotic factors were studied. The score of acute CsA toxicity 
significantly decreased in the CsA + MZR group compared to the CsA group (p < 0.01). MZR and 
MZR + LSRT reduced tubulointerstitial fibrosis and TGF-β1 mRNA expression at 7 weeks. Osteopontin 
(OPN) mRNA expression was decreased at 7 weeks in MZR + LSRT (p < 0.01). Glomerular area 
decreased CsA group and recovered in MZR (p < 0.01) and MZR + LSRT (p < 0.01) at 7weeks. This study 
demonstrated that MZR and LSRT had suppressive effects on inflammatory process in chronic CsA 
nephropathy and led to improvement of tubular damage, tubulointerstitial fibrosis and arteriolopathy 
by down regulation of OPN and TGF-β1 and glomerular size contraction.
Cyclosporine A (CsA) is a calcineurin inhibitor (CNI) which interferes with the calcineurin phosphatase, leading 
to inhibit the production of cytokines such as interleukin-2 needed for the activation of T cells1. Since its intro-
duction in the 1980s in suppressing transplantation rejection, CsA brought a dramatic improvement in transplant 
outcomes in multiple organs2. In addition to inhibition of the action of T-cell-related cytokines, it can also stabi-
lize the actin cytoskeleton of podocytes3.
However, CsA can cause acute and chronic CsA nephrotoxicity4,5. The biggest problem is chronic CsA 
nephrotoxicity after long-term use such as in transplant patients or steroid resistant nephrotic syndrome. The 
incidence of chronic CsA nephrotoxicity is about 30–40% in long-term use and the risk factors are reported to be 
steroid-resistant patients, the duration of CsA treatment, the duration of heavy proteinuria during CsA treatment 
(> 30 days), an age younger than 5 years at the start of CsA and higher CsA trough or C2 (CsA level 2 hours after 
administration) drug levels6–10.
There have been some studies on the protective effects of various drugs such as mycophenolate mofetil, miz-
oribine and RAS blocekrs on chronic CsA nephrotoxicity in animals11–13. However, there has been no report on 
the effect of these drugs on acute or chronic CsA nephrotoxicity regarding glomerular growth in young rats. 
In addition, because a younger age at the start of CsA is one of the factor for the development of chronic CsA 
nephrotoxicity in children with nephrotic syndrome8, we thought that understanding of acute or chronic CsA 
nephrotoxicity in young animals might provide an insight on the pathophysiology of CsA nephrotoxicity in 
children.
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The aim of this study was to evaluate the influence of cyclosporine A (CsA) on glomerular growth and the 
protective effect of concurrent administration of mizoribine (MZR) and losartan (LSAR) on CsA-induced acute 
and chronic nephropathy in young rats.
Results
Changes in body weight and blood chemistry results after 4-week administration of CsA. At 
the first experiment, in CsA/LSRT (100 mg/L) group, the proportion of young rats who survived 4 weeks after 
CsA administration was low and survived mice also did not eat well and the weight gain was blunted. The dose 
of LSRT was determined as 50 and 100 mg/L with the same dose to a similar age of rats from other experiments. 
We speculate that the dose of LSRT capacity (50 and 100 mg/L) was not tolerable in young rats administered in 
combination with CsA.
At 4 weeks after administration of CsA, there was no difference in the degree of increase in body weight 
between the CsA group and the control (olive oil as a vehicle) group. The CsA + LSRT 100mg/L group showed 
significantly decreased weight gain without statistical significance (see Supplementary Table S1). There was no 
significant difference in blood CsA concentration among the groups. Compared to the CsA group, serum BUN 
levels were significantly decreased in the CsA + MZR group (p < 0.01) and serum creatinine levels were signifi-
cantly decreased in the CsA + MZR group and CsA + LSRT 50 mg/L + MZR group (p < 0.01) (see Supplementary 
Table S2).
Histological renal toxicity after 4-week administration of CsA. After 4-week administration of CsA, 
the typical chronic CsA nephrotoxicity did not appear clearly and vacuolization and detachment from the tubular 
basement membrane were shown which are mainly the phenomenon of the acute tubular damage. The score of 
acute CsA toxicity was significantly higher in the CsA group compared to that in the control group (p < 0.01) 
and it significantly decreased in the CsA + MZR group compared to the CsA group (p < 0.01). However, the 
CsA + LSRT group did not show significant changes in the score compared to the CsA group (Table 1 and Fig. 1).
Changes in glomerular area after 4-week administration of CsA. Glomerular area (Bowman’s 
and the glomerular tuft) significantly decreased in the CsA group than that in control group (VH group) 
(p < 0.01). Glomerular area was significantly increased in the CsA + LSRT (50mg/L), CsA + MZR, CsA + LSRT 
(50 mg/L) + MZR compared to that in the CsA group (Table 2). The weight of kidneys showed a decrease in all 
the groups compared to the control group (p < 0.05) (Table 2).
Osteopontin (OPN, spp1) and TGF-β1 mRNA using quantitative real-time PCR and immuno-
histochemistry after 4-week administration of CsA. Osteopontin (Secreted Phosphoprotein 1) OPN 
(spp1) mRNA expression in renal tissue using the quantitative real-time PCR was significantly higher in the 
CsA group compared with the control group (p < 0.01) and significantly lower in CsA + MZR group (p < 0.01), 
CsA + LSRT group (p < 0.03), CsA + MZR + LSRT group (p < 0.02) than in the CsA group. TGF-β 1 mRNA 
expression in renal tissue was significantly higher in the CsA group compared with the control group (p < 0.01) 
and significantly lower in the CsA + LSRT group (p < 0.05) and CsA + MZR + LSRT group (p < 0.05) than in 
the CsA group. (see Supplementary Table S3, Fig. 2). Immunohistochemistry of osteopontin and TGF-β 1 after 
4-week administration of CsA is presented in Supplementary Figure S1.
Changes in body weight and blood chemistry results after 7-week administration of 
CsA. According to prior experience of intolerability in the first experiment, we adjusted the dose of LSRT to 
Treatment groups N
Vacuolization and drop out of 
tubular epithelial cell
No. of 
positive cases P value
VHa 10
Absent to mild 10  < 0.01a
Moderate to severe 0
CsAa,b 15
Absent to mild 4
Moderate to severe 10
CsA + L(50mg/L) 3
Absent to mild 2
Moderate to severe 1
CsA + L(100mg/L) 4
Absent to mild 4
Moderate to severe 0
CsA + Mb 12
Absent to mild 9  < 0.01b
Moderate to severe 3
CsA + L(50mg/L) + M 4
Absent to mild 4
Moderate to severe 0
CsA + L(100mg/L) + M 2
Absent to mild 2
Moderate to severe 0
Table 1.  Acute tubular changes in rat kidney after treatment of CsA for 4 weeks. N; number of subjects, 
VH; vehicle (olive oil), M; mizoribine, L; losartan, CsA; cyclosporine A, Score of acute CsA toxicity (% of 
vacuolization and drop out of tubular epithelial cell); 0: none, 1: < 25%, 2: 25–50%, 3, > 50%.
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35 mg/L at the second experiment for chronic renal toxicity and this experiment showed that the growth state of 
the rats was good.
Body weight decreased significantly in the CsA group compared with the control group (p < 0.05) (see 
Supplementary Table S4). BUN levels were significantly increased in the CsA group (p < 0.05), while serum cre-
atinine levels did not differ between the CsA group and the control group (see Supplementary Table S5).
Histological chronic renal toxicity after 7-week administration of CsA. When the typical histolog-
ical findings in chronic CsA nephrotoxicity was scored after 7-week administration of CsA, the score of tubular 
atrophy, interstitial fibrosis and mononuclear cell infiltration was significantly higher in the CsA group compared 
to that in the control group (p < 0.01). There was no difference in tubular atrophy and mononuclear cell infil-
tration among the CsA-treated groups, but interstitial fibrosis was significantly lower in the CsA + MZR group 
(p < 0.01), and the CsA + LSRT + MZR group (p < 0.05) compared to the CsA alone group (Table 3 and Fig. 3). 
Arteriolar lesions were significantly higher in the CsA group compared with the control group (p < 0.01), but 
those decreased significantly in the CsA + LSRT + MZR group compared with the CsA alone group (p < 0.05) 
(Table 4 and Supplementary Figure S2).
Changes in glomerular area after 7-week administration of CsA. Kidney weight decreased signif-
icantly in the CsA group (p < 0.01) than in the control (VH group) group, but there was no difference among 
CsA-treated groups. The glomerular bowman’s area, and the glomerular tuft area were significantly reduced in 
the CsA group compared with the control group (VH group) (p < 0.01), but those were significantly increased in 
CsA + MZR and CsA + LSRT + MZR groups (p < 0.01) (Table 5).
Figure 1. Acute tubular change in rat kidney due to CsA nephrotoxicity after 4 weeks. CsA-treated group 
showed significant increase of tubular epithelial vacuolar degeneration and drop out. Mizoribine-treated group 
showed significant lesser histologic change than CsA treated group (PAS stain, × 400).
Treatment groups N Glomerular Bowman’s area (105μm2) Glomerular tuft area (105μm2) Kidney weight (g)
VH 10 12.99 ± 1.37a 10.72 ± 1.59a 1.43 ± 0.10*
CsA 15 8.51 ± 1.18a,b,c,d 6.67 ± 1.51a,b,c,d 1.03 ± 0.09*
CsA + L(50mg/L) 3 12.30 ± 1.19b 10.29 ± 0.70b 1.25 ± 0.17*
CsA + M 12 11.06 ± 1.22c 8.29 ± 1.06c 1.11 ± 0.14*
CsA + L(50mg/L) + M 4 11.62 ± 1.59d 10.56 ± 2.64d 1.07 ± 0.12*
Table 2.  Glomerular area and kidney weight after treatment of CsA for 4 weeks. N; number of subjects ,VH; 
Vehicle (olive oil), M; Mizoribine, L; Losartan, CsA; cyclosporine A, Data are expressed as mean ± SD a,b,c,dp < 0.01 
(glomerular Bowman’s and tuft area), *p < 0.05 (kidney weight, all groups vs. VH).
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Osteopontin (OPN, spp1) and TGF-β1 mRNA using quantitative real-time PCR and immuno-
histochemistry after 7-week administration of CsA. After 7-week administration of CsA, renal OPN 
(spp1) and TGF-β 1 mRNA expression in the CsA alone group increased by 1.4 and 3.5 times, respectively, com-
pared to the control group (VH) (p < 0.01). Compared to the CsA alone group, renal OPN (spp1) mRNA expression 
was significantly reduced in the CsA + LSRT + MZR group (p < 0.05) and renal TGF-β 1 mRNA expression was 
significantly reduced in the CsA + MZR and CsA + LSRT + MZR group (p < 0.01) (see Supplementary Table S6 
and Fig. 4).
Immunohistochemistry of osteopontin and TGF-β 1 after 7-week administration of CsA is presented in 
Supplementary Figure S3.
Changes in anti-rat ED-1 positive cells CsA after 7-week administration of CsA. After 7-week 
administration of CsA, ED-1 positive cells were significantly increased in the CsA-treated groups than in the 
control (VH) (p < 0.01) compared with the CsA alone group on the immunohistochemistry and those were sig-
nificantly decreased the CsA + MZR and the CsA + LSRT + MZR groups (p < 0.01) (see Supplementary Table 
S7, Supplementary Figure S4).
Discussion
CsA nephrotoxicity is divided into acute and chronic forms. Acute CsA nephrotoxicity occurs through acute 
reversible vascular contraction by direct toxicity of the renal vessels and a decrease in glomerular filtration rate by 
systemic hemodynamic changes to CsA treatment14,15 and renal function can be normalized if the use of CsA is 
stopped. The characteristic histological changes may represent vacuolization and detachment of the tubular cells 
and activation of the sympathetic nervous system and the renin-angiotensin system (RAS), endothelin (ED)-1, 
nitric oxide has been known to be involved in acute CsA nephrotoxicity16–19.
The pathogenic mechanism of chronic CsA nephrotoxicity is not clear, but appears to be involved in direct 
tubular injury or vascular injury and chronic ischemia in kidneys, leading to tubular atrophy and interstitial 
fibrosis4,5,20,21. If the damage of renal tubular cells and interstitium is caused by CsA, renal tubular cells are mainly 
eliminated by apoptosis22,23 and renal injury progresses through hyperactivation of the immune mediators such as 
angiotensin II, transforming growth factor (TGF)-β 1, osteopontin (OPN) and macrophages in addition to direct 
toxic effects of CsA24,25.
ED-1 has a strong vasoconstrictor action and is involved in the renal blood flow, glomerular filtration rate, 
reabsorption of sodium by controlling vascular tone18. It can also affect the glomerular histological changes 
through accumulation of the extracellular matrix and interstitial fibrosis18. OPN is primarily expressed in the 
distal tubule and Henle’s loop of the renal medulla and is not expressed normally in the renal cortex17,24. CsA 
administration can cause macrophage infiltration and interstitial fibrosis by increasing the expression of OPN 
in the kidneys17,24. TGF-β 1 is known to be an important cytokine in the pathogenesis of glomerulosclerosis and 
tubulointerstitial fibrosis25 and expression of TGF-β 1 increased in proportion to the CsA dose. An increase of 
Figure 2. Expression of osteopontin (spp1) and TGF-β1 mRNA in rat kidney detected by real-time 
PCR. (Abbreviations: VH; vehicle (olive oil), M; mizoribine, L; losartan, CsA; cyclosporine A, spp1; Secreted 
Phosphoprotein 1, TGF; transforming growth factor, Data are expressed as mean ± SD).
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TGF-β 1 by CsA is connected to the tubulointerstitial fibrosis through an increase in extracellular matrix and RAS 
activation26,27.
The prevention of chronic CsA nephrotoxicity is to stop or reduce the use of the calcineurin inhibitor, but 
the long-term use is inevitable in some patients with transplantation or steroid resistant nephrotic syndrome. 
Histological changes due to CsA persist or progress even after stopping the drug21. Therefore, the development 
and application of drugs inhibiting important mechanisms that can cause chronic CsA nephrotoxicity may be the 
best way to block irreversible renal histological changes such as tubulointerstitial fibrosis beforehand28.
In our study, we selected the MZR and LSRT for the potential drugs whether these drugs could prevent acute 
and chronic CsA nephrotoxicity based on previous studies12,13. MZR is extracted from the Eupenicillium brefeld-
ianum as a purine nucleotide analog29, and has been used in the treatment of lupus nephritis and nephrotic syn-
drome30. Previous studies showed that MZR inhibits macrophage infiltration which has an important role in the 
development of interstitial fibrosis in rats with obstructive renal disease31,32.
We found that 4-week administration of CsA did not cause the development of a typical chronic CsA nephro-
toxicity and rather showed the findings of acute CsA nephrotoxicity such as vacuolization and detachment from 
the tubular basement membrane of renal tubular cells. Although there has been no previous report on the effect 
of mizoribine on acute CsA nephrotoxicity, we showed that MZR had a beneficial effect on the acute renal tubular 
changes by CsA through decreasing renal expression of OPN and TGF-β 1. However, this effect was not observed 
in LSRT-treated group in our study. We also demonstrated that MZR and LSRT had protective effects on inflam-
matory process in chronic CsA nephropathy and led to improvement of tubular damage, tubulointerstitial fibrosis 
and arteriolopathy by down regulation of OPN and TGF-β 1, which were similar to a few previous studies.
However, previous researches have not investigated whether the MZR or LSRT might have a beneficial effect 
on glomerular growth12,13, which could be decreased by CsA. We thought that measurement of glomerular 
growth will be important because long-term use of CsA is also inevitable in some children as well as in adults and 
a younger age at the start of CsA is known to be one of the important factor for the development of chronic CsA 
nephrotoxicity in children with nephrotic syndrome8. It was reported that the glomerular growth in rats increases 
linearly from the age of five weeks to two years with increasing age33. A previous report showed that long-term 
administration of CsA resulted in a reduction in glomerular volume, especially volume of the glomerular vascular 
Treatment groups N Histologic changes
No. of 
positive 
cases P value
Tubular atrophy
 VHa 6
Absent to mild 6  < 0.01a
Moderate to severe 0
 CsAa 8
Absent to mild 5
Moderate to severe 3
 CsA + M 6
Absent to mild 4
Moderate to severe 2
 CsA + L(35m/L) + M 4
Absent to mild 4
Moderate to severe 0
Interstitial fibrosis
 VHb 6
Absent to mild 6  < 0.01b
Moderate to severe 0
 CsAb,d,e 8
Absent to mild 2
Moderate to severe 6
 CsA + Md 6
Absent to mild 6  < 0.01d
Moderate to severe 0
 CsA + L(35m/L) + Me 4
Absent to mild 4  < 0.05e
Moderate to severe 0
Mononuclear cell infiltration
 VHC 6
Absent to mild 6  < 0.01C
Moderate to severe 0
 CsAC 8
Absent to mild 2
Moderate to severe 6
 CsA + M 6
Absent to mild 3
Moderate to severe 3
 CsA + L(35mgL) + M 4
Absent to mild 3
Moderate to severe 1
Table 3.  Tubulointerstitial changes due to chronic CsA nephrotoxicity after CsA treatment for 7 weeks. N; 
number of subjects, VH; vehicle (olive oil), M; mizoribine, L; losartan, CsA; cyclosporine A, Score of chronic 
CsA toxicity by incidence of tubular atrophy, interstitial fibrosis, mononuclear cell infiltration (0: none, 1: < 25%, 
2: 25–50%, 3, > 50%).
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Figure 3. Histologic change due to chronic CsA nephrotoxicity after 7 weeks. CsA-treated group 
showed significant increase of interstitial fibrosis due to chronic CsA nephrotoxicity and mizoribine, 
mizoribine + losartan-treated group showed significant lesser interstitial fibrosis than CsA-treated group 
(trichrome stain, × 200).
Treatment groups N Grade of arteriolopathy due to CsA nephrotoxicity No. of positive cases P value
VHa 6
Absent to mild 6
 < 0.01a
Moderate to severe 0
CsAa,* 8
Absent to mild 0
Moderate to severe 8
CsA + M 6
Absent to mild 0
 
Moderate to severe 6
CsA + L(100mg/L) + M* 4
Absent to mild 2
 < 0.05*
Moderate to severe 2
Table 4.  Arteriolopathy after CsA treatment for 7 weeks. N; number of subjects, VH; vehicle (olive oil), M; 
mizoribine, L; losartan. CsA; cyclosporine A, Score of arteriolopathy due to chronic CsA toxicity (0: none, 1: 
rare and non-circumferential, 2: frequent and non-circumferential, 3: circumferential).
Treatment groups N Glomerular Bowman’s area (105μm2) Glomerular tuft area (105μm2) Kidney weight (g) (Mean ± SD)
VH 6 13.86 ± 1.29a 11.37 ± 0.99a 1.65 ± 0.02*
CsA 8 8.54 ± 1.81a,b,c  7.75 ± 0.87a,b,c 1.10 ± 0.20*
CsA + M 8 12.82 ± 1.66b 10.60 ± 1.57b 1.06 ± 0.12
CsA + L(35mg) + M 4 12.42 ± 1.93c 9.75 ± 1.91c 1.43 ± 0.01
Table 5.  Glomerular areas and kidney weight after treatment of CsA for 7 weeks. N; number of subjects, 
VH; vehicle (olive oil), M; mizoribine, L; losartan, CsA; cyclosporine A, Data are expressed as mean ± SD 
a,b,cp < 0.01 (glomerular Bowman’s and tuft area), *p < 0.05 (kidney weight).
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ring in rats34 and the impact of CsA on glomerular volume has also been reported both in adults and children, 
including our previous study35,36. Because glomerular growth is more active during childhood than during adult-
hood, we thought that the effect of CsA might be greater in children than in adults and effective inhibition of renal 
toxicity with the MZR or LSRT could also affect glomerular growth.
We firstly demonstrated that glomerular area significantly decreased in the CsA group than that in control 
group after 4-week and 7-week administration of CsA, which were reversed by coadministration of MZR and 
LSRT. Glomerular area was measured with both the Bowman’s capsule and glomerular vascular ring area and 
both glomerular areas were decreased, but the reduction of Bowman’s capsule area was more prominent in the 
CsA group. Both glomerular areas were improved and Bowman’s capsule area was well-maintained after MZR 
or LSRT treatment. These results suggest that there has been the collapse of the Bowman’s space and glomerular 
vascular ring area through progression of interstitial fibrosis by CsA, which was improved by MZR or LSRT.
Regarding the dose of losartan, the rats showed growth failure and a reduced survival due to intolerability of 
LSRT (100 mg/L) in the first experiment, but the rats showed good tolerance and growth to the adjusted dose of 
LSRT (35 mg/L) in the second experiment. Because co-administration of LSRT (35 mg/L) with CsA demonstrated 
the inhibitory effect for chronic nephrotoxicity and impairment of glomerular growth by CsA, it is thought to 
require a consideration for the tolerability of LSRT by dose adjustment.
In conclusion, our study demonstrated that MZR and LSRT had protective effects on inflammatory process 
in acute and chronic CsA nephropathy and led to improvement of tubular damage, tubulointerstitial fibrosis and 
arteriolopathy by down regulation of OPN and TGF-β 1 and glomerular size contraction. Given these results, we 
speculate that MZR and LSRT can be used alone or in combinations as the potential antagonists for the inhibition 
of CsA nephrotoxicity. Further studies are necessary to evaluate the combined use of these drugs with CsA could 
prevent chronic CsA nephrotoxicity and glomerular area contraction in nephrotic children who are receiving 
long-term CsA treatment.
Materials and Methods
Experimental animals and groups. The 6-week-old male Sprague-Dawley rats were bred under specif-
ic-pathogen-free (SPF) conditions and low salt diet (0.05%). At the first experiment, they were divided into eight 
experimental groups and CsA were administered for 4 weeks. Then they were sacrificed and kidney biopsies were 
performed to investigate the expression of acute renal toxicity. At the second experiment, CsA were administered 
for 7 weeks and investigated chronic CsA nephrotoxicity.
(A) The control group (VH): CsA vehicle (olive oil) group
(B) VH + Losartan (LSRT) group
(C) VH + Mizoribine (MZR) group
(D) CsA group
(E) CsA + LSRT group
(F) CsA + MZR group
(G) CsA + LSRT + MZR group
Experimental drugs. A. Cyclosporine A (CsA) (Novartis Pharma Co., USA). CsA was dissolved in the olive 
oil (Sigma Co., St. Louis, MO) as a vehicle and a final concentration of 15 mg/mL was made, which was adminis-
tered subcutaneously with the dose of 15 mg/kg/day.
B. Losartan (LSRT). LSRT was dissolved in purified water at a concentration of 100 mg/L and mixed with the 
drinking water and then administered (target volume; 30 mg/kg/day) in the first experiment during 4 weeks, and 
Figure 4. Expression of osteopontin (spp1) and TGF-β mRNA in rat kidney detected by real-time PCR. 
(Abbreviations: VH; vehicle (olive oil), M; mizoribine, L; losartan, CsA; cyclosporine A, spp1; Secreted 
Phosphoprotein 1, TGF; transforming growth factor, Data are expressed as mean ± SD).
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at the second experiment the dose of LSRT reduced to 35 mg/L during 6 weeks because of intolerability showed 
in the first experiment.
C. Mizoribine (MZR) (Bredinin: Asahi Chemical Industry Co., Japan). MZR was dissolved in normal saline 
to make a final concentration of 5 mg/mL and administered with the dose of 5 mg/kg/day by intraperitoneal 
injection.
Histological CsA nephrotoxicity and semi-quantitative scoring. We checked the CsA nephro-
toxicity 4 and 7 weeks after CsA administration using PAS and trichrome stain by light microscopy in each 
group. Histological nephrotoxicity was classified as non-specific acute tubular changes and characteristic chronic 
nephrotoxicity according to the tissue changes caused by CsA using a semi-quantitative scoring system in each 
group.
A. Acute tubular changes. They were semiquantitatively scored as 1–4 points according to the proportion of 
tubular cells which showed vacuolization and detachment from the tubular basement membrane (1 point: none, 
2 points: < 25%, 3 points: 25–50% and 4 points: > 50%).
B. Tubulointerstitial changes due to chronic renal toxicity. They were semiquantitatively scored as 1–4 points 
according to the proportion of tubular cells showed tubular atrophy, interstitial fibrosis and mononuclear infiltra-
tion (1 point: none, 2 points: < 25%, 3 points: 25–50%, 4 points: > 50%).
C. Arteriolar lesions caused by chronic renal toxicity (arteriolopathy). They were semiquantitatively scored 
as 1–4 points according to the proportion and type of arteriolar changes (1 point: none, 2 points: < 50% and 
non-circumferential, 3 points: > 50% frequent and non-circumferential and 4 points: circumferential).
Measurement of glomerular area. Renal tissue was PAS stained and magnified (× 400) by light micro-
scope. The image was captured and switched to JPEG file. Using JPEG image files converted by using a computer 
program Image Pro Plus, the glomeruli which have the pole of the glomerular vasculature were selected and the 
Bowman’s capsule and glomerular vascular ring were traced and 15 glomerular area in each experiment object 
was measured.
Real-time reverse transcription polymerase chain reaction (RT-PCR). The expression levels of OPN 
and TGF-β 1 were measured by real-time RT-PCR using Taqman probe which has a fluorescent dye that is only 
at the end of 5′ . Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used as a control. Amplification 
and detection equipment was LightCycler480 (Roche, Germany) and PCR reaction profile was as follows (50 °C 
2 minutes, 95 °C 15 minutes, 1 cycle, 95 °C 15 seconds, 60 °C 1 minute 40 cycles).
Immunohistochemistry. The paraffin embedded tissue was dissected as 4 μm in thickness for immunohis-
tochemical staining and paraffin was removed by xylene. It was processed with hydration in a high concentration 
to a low concentration of alcohol and then washed with distilled water and put it in citrate buffer (pH 6.0) and was 
treated twice for 5 minutes in a microwave oven. After cooling at room temperature, it was washed for 10 min in 
Tris buffer and for 10 minutes in 0.3% hydrogen peroxide, thereby inhibiting the endogenous peroxidase activity. 
After washing for 10 minutes in Tris buffer and for 15 minutes in normal blocking solution, it was reacted with 
the primary antibody for OPN (Abcam, Cambridge, UK, 1: 200), TGF-β 1 (Serotec, Oxford, UK, 1: 500), anti-rat 
ED- 1 (CD68) (Serotec, Oxford, UK, 1: 200).
Using LSAB kit (DAKO, Denmark), it was sequentially reacted with secondary antibody coupled to biotin and 
streptavidin-biotin peroxidase. It was stained with the diaminobenzidine (DAB) and then counterstained with 
Harris hematoxyline, and the differences in expression in control and treated animals were analyzed.
We counted ED-1 (+) cells per high power field on microscopy which were represented as the average by 
counting the area of the 3 different areas.
Blood chemistry tests. After administration of experimental drugs, blood chemistry tests (blood urea 
nitrogen [BUN], creatinine, cholesterol, triglyceride) and blood CsA concentrations were measured. Whole blood 
CsA concentrations were measured by monoclonal radioimmunoassay. CsA levels and blood chemistry tests 
were performed after last administration of CsA and just before sacrifice of rats. In untreated controls, sampling 
data before sacrifice were used and therefore, we did not perform blood sampling in all groups prior to drug 
administration.
Statistical analysis. The data was analyzed to compare the mean differences between the experimental and 
control group by an independent t-test and ANOVA using SPSS for Windows, version 18.0 (SPSS Inc., Chicago, 
Illinois, USA). All differences were considered significant at a value of P < 0.05.
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